Leprosy Treatment Market Business Opportunities, Current Trends, Challenges and Market Analysis 2028

Poojasalve34

222
views

Leprosy Treatment Market

Leprosy is very common in developing nations. Monotherapy, or the use of just one anti-leprosy medicine, is likely to cause microorganisms to become resistant to that drug. Thus, multidrug therapy (MDT) is a common leprosy treatment. The World Health Organization (WHO) Expert Group first suggested multidrug treatment in 1984.

Since 1995, the WHO has provided MDT at no cost to all endemic nations. The most widely used antileprotic drug is rifampicin. It works for both types of leprosy. The WHO recommends a combination of rifampicin, clofazimine, and dapsone for the treatment of multibacillary leprosy, while paucibacillary leprosy is treated with rifampicin and dapsone.

High prevalence serves as a reminder that some regions of the world have both high incidence and high transmission rates of the disease. The WHO estimates that approximately 16 million leprosy cases have been treated over the past 20 years. Governments and governing entities alike are working to end the disease's existence on a global basis. These reasons will cause the market for Leprosy Treatment Market to expand significantly throughout the forecast period (2016–2024).

Recent clinical trials have demonstrated the effectiveness of quinolones such ofloxacin, azithromycin, and minocycline against Mycobacterium leprae. Patients with paucibacillary leprosy should get a single dosage of minocycline, rifampin, or ofloxacin, according to the WHO.